Deutsche Bank Ag\ Lineage Cell Therapeutics, Inc. Transaction History
Deutsche Bank Ag\
- $248 Billion
- Q4 2024
A detailed history of Deutsche Bank Ag\ transactions in Lineage Cell Therapeutics, Inc. stock. As of the latest transaction made, Deutsche Bank Ag\ holds 174,702 shares of LCTX stock, worth $118,797. This represents 0.0% of its overall portfolio holdings.
Number of Shares
174,702
Previous 59,030
195.95%
Holding current value
$118,797
Previous $53,000
64.15%
% of portfolio
0.0%
Previous 0.0%
Shares
16 transactions
Others Institutions Holding LCTX
# of Institutions
134Shares Held
106MCall Options Held
22.1KPut Options Held
0-
Broadwood Capital Inc New York, NY41.7MShares$28.3 Million1.65% of portfolio
-
Black Rock Inc. New York, NY9.56MShares$6.5 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.63MShares$5.87 Million0.0% of portfolio
-
Perceptive Advisors LLC New York, NY7.24MShares$4.92 Million0.12% of portfolio
-
Defender Capital, Llc.5.96MShares$4.06 Million1.17% of portfolio
About Lineage Cell Therapeutics, Inc.
- Ticker LCTX
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 169,755,008
- Market Cap $115M
- Description
- Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...